

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 624 376 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**15.03.2000 Bulletin 2000/11**

(51) Int. Cl.<sup>7</sup>: **A61K 39/095**, A61K 39/40

(21) Application number: **94106827.2**

(22) Date of filing: **02.05.1994**

(54) **Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci**

Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken

Préparation et utilisations de protéines de membranes externes dépourvues de LOS à partir de coques gram-négatifs

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT  
SE**  
Designated Extension States:  
**SI**

(30) Priority: **13.05.1993 US 61581**

(43) Date of publication of application:  
**17.11.1994 Bulletin 1994/46**

(73) Proprietor:  
**AMERICAN CYANAMID COMPANY**  
**Wayne New Jersey 07470 (US)**

(72) Inventor: **Zlotnick, Gary W.**  
**Penfield, New York 14526 (US)**

(74) Representative:  
**Wächtershäuser, Günter, Prof. Dr.**  
**Patentanwalt,**  
**Tal 29**  
**80331 München (DE)**

(56) References cited:  
**EP-A- 0 073 169** **EP-A- 0 301 992**  
**EP-A- 0 351 604** **WO-A-93/03761**

• **ANTONIE VAN LEEUWENHOEK JOURNAL OF  
MICROBIOLOGY** vol. 53, no. 6 , 1987 ,  
**DORDRECHT** pages 413 - 419 J. T. POOLMAN ET  
AL. 'COMPARISON OF MENINGOCOCCAL  
OUTER MEMBRANE PROTEIN VACCINES  
SOLUBILIZED WITH DETERGENT OR C  
POLYSACCHARIDE.'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 624 376 B1**

## Description

### Background

5 **[0001]** Antoine van Leeuwenhoek (1987), 53: 413-419 discloses the isolation of outer membrane proteins by detergent extraction of bacteria.

**[0002]** Bacterial meningitis is an inflammatory disease of the central nervous system caused by the growth of bacteria in and adjacent to the leptomeninges. It is an acute, and often lethal, infectious disease that affects children and young adults. One of the most common causes of bacterial meningitis worldwide is infection with *Neisseria meningitidis*. The occurrence of infection with this bacterium is unpredictable, since many people become colonized without exhibiting the disease. Some people are temporary carriers, while others are chronic carriers, discharging meningococci either more or less continuously or in a sporadic fashion. During the course of infection, bactericidal antibodies are produced in the infected person, which apparently immunize the person against subsequent infection (Goldschneider *et al.*, 1969). This observation has led to the expectation that vaccines based on bacterial antigens may be effective against meningitis.

10 **[0003]** *N. meningitidis* is a Gram-negative coccus. Characteristically, it is surrounded by a cell envelope composed of an inner plasma membrane, a periplasmic space, and an outer membrane or cell wall. The outer membrane is composed of lipooligosaccharide (LOS) molecules, lipids, proteins and polysaccharides. The protective antibodies produced in infected people were found to be directed against both the capsular polysaccharides and the outer membrane proteins (Frasch, 1983).

15 **[0004]** Strains of *N. meningitidis* have been classified into serogroups according to the type (antigenically and biochemically) of the capsule. Currently recognized serogroups include A, B, C, D, W135, X, Y, Z and 29E. The polysaccharides responsible for the serogroup specificity of groups A, B, C, X, W135 and Y have been purified. A tetravalent vaccine based on purified capsular polysaccharides from serogroups A, C, Y and W 135 has been developed (Hankins *et al.*, 1982). However, the lack of immunogenicity in the under 2 years age group, the age group most at risk from meningococcal infection, has limited the usefulness of this vaccine. The capsule of Group B *N. meningitidis* is poorly immunogenic in all age groups, even when conjugated to a carrier protein. There is evidence that antibodies to this capsule may cross react with brain tissue of fetal and newborn infants.

20 **[0005]** The major outer membrane proteins (omp) of *N. meningitidis* have been divided into five classes on the basis of structural similarities, as determined by migration (Mr) on SDS-polyacrylamide gels and peptide map analysis (Tsai *et al.*, 1981). Of these protein classes, the class 1 protein appears to be the most interesting for vaccine production. This antigen seems to be a major immunodeterminant in humans. It is expressed in most isolates of *N. meningitidis* and is the basis for subtype specificity of strains.

25 **[0006]** Several attempts have been made to produce a vaccine based on outer membrane proteins. Vaccines composed of capsular polysaccharide and outer membrane proteins, or just outer membrane proteins in a vesicular complex, have been tested. Only one of these vaccines has been reported to be more than 57% effective (Sierra *et al.*, 1991).

30 **[0007]** Another significant problem in the development of both outer membrane and capsule based vaccines is the presence of the bacterial lipooligosaccharide (LOS), which produces toxic side effects in humans. LOS is also referred to as bacterial endotoxin. Low amounts of LOS can cause fevers, and high doses of LOS can result in a general wasting (cachexis) of the patient. The most recent outer membrane complex vaccines have had residual LOS levels of 10-70 µg/mg protein (see Zollinger, 1990 for review). Thus, there exists a need for safe and effective vaccines for bacterial meningitis caused by *N. meningitidis*, and especially for disease caused by Group B strains.

### Summary of the Invention

45 **[0008]** This invention relates to a method for the effective removal of lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci by sequential extractions with certain detergents. LOS, which is also referred to as bacterial endotoxin, can cause undesirable side effects in vaccines, such as fever. As described herein, the method produces outer membranes and soluble outer membrane proteins with an extremely low content of LOS, but which retain immunogenicity. These LOS-depleted outer membrane products are further shown to elicit bactericidal antibodies. Thus, vaccines comprising LOS-depleted outer membranes and soluble outer membrane proteins are provided, which are expected to be useful in therapy and prophylaxis against meningitis and other diseases caused by Gram-negative cocci.

50 **[0009]** Specifically described herein are outer membrane products of *Neisseria meningitidis*. Outer membrane products prepared from *N. meningitidis* by the present method are shown to have a LOS content of less than about 0.01% (wt./wt. total protein) and to elicit bactericidal antibodies in animals. As a result, vaccines against neisserial meningitis are provided, which are immunogenically effective and relatively free of bacterial LOS. Of particular interest is a vaccine against serogroup B strains of *N. meningitidis*, for which there is presently no effective vaccine.

**[0010]** The present method is expected to also be applicable to other Gram-negative cocci, since these bacteria have structurally similar outer membranes. For example, LOS-depleted outer membranes of other *Neisseria* species, such as *N. gonorrhoeae*, and other Gram-negative cocci, such as *Moraxella*, can be prepared. Thus, *N. meningitidis* is representative of other Gram-negative cocci in the procedures and products described below.

**[0011]** This method is further applicable to various natural strains of Gram-negative cocci, as well as to recombinant strains that are genetically engineered to produce more than one subtype-specific epitope, e.g., more than one class 1 protein of *N. meningitidis*. Multivalent vaccines can be prepared using mixtures of strains or recombinant strains expressing the surface epitopes of several serogroups, serotypes or subtypes.

**[0012]** The method comprises sequential extractions with different kinds of detergents. First, total membranes of the cocci are extracted with a polyoxyethylene detergent (e.g., TRITON X-100™, BRIJ35™, or TWEEN80™), resulting in outer membranes that are depleted of inner membranes and some of the LOS. This is followed by extraction of the outer membranes with a zwitterionic betaine detergent, such as one of the ZWITTERGENT™ series (e.g., 3-12 or 3-14) or EMPIGEN BB™. These detergents specifically remove essentially all of the remaining LOS while extracting very little protein.

**[0013]** The resulting LOS-depleted outer membrane preparation is composed of outer membrane proteins (omps) complexed with cell wall components. This preparation can be used for vaccine purposes directly, or the omp can be solubilized and extracted from the other cell wall components using a zwitterionic betaine detergent in a salt buffer, e.g., with ZWITTERGENT 3-14™ in about 0.1 to about 0.5 M NaCl. The solubilization step results in LOS-depleted fractions, one containing soluble outer membrane proteins and another containing insoluble outer membrane proteins complexed with other cell wall components. Both LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins are shown to elicit bactericidal antibodies in mice.

#### Brief Description of the Drawing

**[0014]** The figure is a flow diagram of a method for preparing LOS-depleted soluble outer membrane proteins from *N. meningitidis*.

#### Detailed Description of the Invention

**[0015]** An effective method is described herein for removing the toxic lipooligosaccharides (LOS) from outer membrane preparations of Gram-negative cocci, as exemplified by *Neisseria meningitidis*. The method is simple and results in a lower content of LOS than achieved with previous methods for detoxifying outer membrane preparations. In addition, LOS is removed without significant loss of immunogenicity.

**[0016]** The method involves sequential extractions with different types of detergents. First, total membranes of the cocci are extracted with a polyoxyethylene detergent, such as TRITON X-100™, BRIJ35™ or TWEEN80™. This removes the inner membranes and some of the LOS. Then, the outer membranes are extracted with a zwitterionic betaine detergent, such as one of the ZWITTERGENT™ series (e.g., 3-12 or 3-14) or EMPIGEN BB™. This step removes essentially all of the remaining LOS, resulting in LOS-depleted, protein-enriched outer membrane complexes (referred to as LOS-depleted outer membranes). Trace amounts of LOS may remain, depending on the particular zwitterionic detergent used; however, these levels are low and are not expected to induce toxic side effects in humans.

**[0017]** The preferred procedure is to extract several times with TRITON X-100™ followed by several extractions with ZWITTERGENT 3-14™ (Zw3-14). For example, LOS-depleted outer membranes are prepared from a serogroup B strain, such as H44/76, 2996 or H13. Bacterial membranes are extracted twice with TRITON X-100™, then at least twice with ZWITTERGENT 3-14™ (see the figure). The resulting yield from one gram of lyophilized bacterial cells is approximately 32 mg of LOS-depleted, protein-enriched outer membranes. This product contains no remaining LOS detectable by silver staining of SDS-polyacrylamide gels.

**[0018]** The LOS-depleted outer membrane product of this method is a complex of outer membrane proteins and cell wall components. To further purify the antigen-preparation, the outer membrane proteins (omps) are solubilized from the LOS-depleted cell walls, preferably, by extraction with a zwitterionic betaine detergent in a salt buffer. ZWITTERGENT 3-14™ in about 0.1 to about 0.5 M sodium chloride is preferred for this purpose. Other zwitterionic detergents and salt buffers, such as potassium chloride, can also be used. The solubilization step yields LOS-depleted soluble outer membrane proteins and a separate fraction containing insoluble omps complexed with other cell wall components. A yield of approximately 16 mg solubilized omps per gram of lyophilized cells is obtained by extracting LOS-depleted cell walls with 1.0% ZWITTERGENT 3-14™ in 0.5 M sodium chloride. More protein can be obtained by repeating this extraction step.

**[0019]** The soluble outer membrane proteins are further concentrated by various standard methods for protein concentration, such as ethanol precipitation, filtration, and absorption. Concentration of the soluble omps permits adjusting the final concentration of the antigens in a vaccine or reagent composition.

**[0020]** The figure illustrates one embodiment of the method for preparing LOS-depleted soluble outer membrane proteins, beginning with whole *N. meningitidis* cells and proceeding to concentration of the soluble outer membrane proteins. Table 1 (at the end of the Detailed Description) shows the LOS and protein contents of the LOS-depleted outer membranes and soluble omps compared with the starting material.

**[0021]** The types of detergent used and the order in which they are used are important to this method. For example, TRITON X-100™ efficiently removes the majority of the LOS from the outer membranes with minimal loss of protein. However, it is ZWITTERGENT 3-14™ that is important for removal of the remainder of the LOS. The order of detergents used is important in determining whether a protein or other cell wall component is extracted or left insoluble. Each detergent has a direct effect on what is solubilized with subsequent detergents. For example, if sarcosyl, instead of TRITON X-100™, is used to extract inner membranes, the protein profile of the resulting outer membranes, as determined by SDS-polyacrylamide gel electrophoresis, is different. The level of class 1 outer membrane protein is also reduced.

**[0022]** Various optimizations of the method described above can be performed in order to maximize LOS removal and minimize protein loss. For example, it is found that the optimum concentration range of Zw3-14 is from about 0.5% to about 1.0% (wt./vol.). Levels lower than 0.5% are not effective at decreasing the endotoxin level. Each extraction step can also be performed more than once. However, extraction with the polyoxyethylene detergents should precede extraction with the zwitterionic detergents. Extracting a number of times may result in cleaner preparations, but may also result in lower yields. Increasing the concentration of detergents may produce the same result with fewer extractions. Combinations of different polyoxyethylene detergents and zwitterionic detergents can also be used in the first and second extraction steps, respectively. For example, after TRITON™ extraction, the outer membranes can be extracted twice with Zw3-12 and twice with Zw3-14.


**[0023]** Total membranes are prepared from the cocci by standard methods for lysing bacterial cells and separating the membrane and cytoplasmic fractions. For example, a French pressure cell is utilized to lyse the bacteria, low speed centrifugation to remove unbroken cells, and ultracentrifugation to recover total membranes. Separation of the desired from the undesired fractions after each extraction can also be performed by a variety of known methods, including centrifugation, filtration, dialysis, and absorption.

#### Detergent Substitutions

**[0024]** Various detergent substitutions can be used in the method and their effectiveness at removing LOS while retaining immunogenicity of the outer membranes tested.

**[0025]** BRIJ™, TRITON X-100™, and TWEEN80™ are polyoxyethylene detergents. BRIJ35™ and TWEEN80™ perform very similarly to TRITON™. Neither reduces the endotoxin level as effectively as TRITON X-100™, but they do not affect the subsequent removal of LOS by ZWITTERGENT 3-14™. Total protein content of the resulting LOS-depleted outer membrane products are similar. Substitution of TRITON X-100™ with sarcosyl results in low endotoxin content (much less than 1.8 ng/mg protein), but the yield of LOS-depleted outer membranes in terms of total protein is much lower than obtained with TRITON™.

**[0026]** The zwitterionic betaine detergents are summarized by the following formula:



where R<sub>1</sub> is an alkyl chain with more than 10 carbons and less than or equal to 16 carbons, R<sub>2</sub> is a sulfonyl group or a carboxyl group, and n is greater than 1 and preferably 2-3. For example, the ZWITTERGENT™ series has R<sub>2</sub> = a sulfonyl group (-SO<sub>3</sub><sup>-</sup>), n = 3, and R<sub>1</sub> alkyl groups of various lengths. The ZWITTERGENT™'s are named after the length of the alkyl chain, e.g., Zw3-12 has an alkyl group with 12 carbons, and Zw3-14 has 14 carbons in R<sub>1</sub>. EMPIGEN BB™ has R<sub>2</sub> = a carboxyl group (-COO<sup>-</sup>), 12 carbons in R<sub>1</sub>, and n = 2.

**[0027]** Of ZWITTERGENTS™ 3-08, 3-10, 3-12 and 3-14, 3-14 is the most effective at removing endotoxin without extracting an excess of protein. The shorter chain detergents (3-08 and 3-10) are significantly less effective at removing LOS and also yield less protein. These results suggest that the chain length of the R<sub>1</sub> alkyl group affects the effectiveness of the detergent at removing LOS. It is possible that Zw3-12 and Zw3-14 are effective because their alkyl chains are about the same length as the aliphatic chains of the LOS molecules. However, detergents with alkyl groups longer than 16 carbons may become insoluble.

[0028] EMPIGEN BB™ functions substantially identically to Zw3-14. It is as effective at reducing the level of endotoxin and extracts the same proteins. It may offer an advantage in that it seems to extract less protein, resulting in increased total protein in the outer membrane products.

[0029] Other detergents that are similar in structure to the ones specifically mentioned herein can be tested for effectiveness in preparing LOS-depleted outer membranes and outer membrane proteins, as described herein. Such detergents would be considered the functional equivalents of the polyoxyethylene detergents in the first extraction step or of the zwitterionic detergent used in the second extraction step or in the solubilization step.

#### Immunogenicity of Outer Membrane Products

[0030] To test the immunogenicity of the outer membrane products of this method, outer membranes (the product after extraction with TRITON X-100™), LOS-depleted outer membranes (the product after extraction with Zw3-14, or Zw3-12 as indicated), and LOS-depleted soluble omps (the product of the solubilization step) are prepared from a recombinant strain (H13) of *N. meningitidis*. Strain H13 (B:-p1.7,16;p1.5,2) is a double mutant cell line derived from the wild type strain H44/76 (B:15:p1.7,16). H13 is devoid of the class 3 and class 5 outer membrane proteins and is genetically engineered to express the p1.5,2 class 1 protein in addition to its natural p1.7,16 class 1 protein. The wild type strain 2996 (B:2B:p1.5,2) expresses the p1.5,2 class 1 protein. Thus, H13 has the class 1 subtypes of both H44/76 and 2996.

[0031] The LOS-depleted outer membrane preparations are tested for immunogenicity by injecting them into mice and analyzing the resulting sera. The sera are collected at 0, 4, and 8 weeks after primary immunization and at exsanguination on week 10 (see Examples). The sera are then tested, by immunoblot analysis and enzyme-linked immunosorbent assay (ELISA), for the presence of antibodies that react with whole cells from strains H44/76 or 2996, as well as for antibodies that recognize purified p1.7,16 class 1 omp.

[0032] Table 2 shows the endpoint ELISA titers of the sera to purified p1.7,16. As seen in this table, the LOS-depleted soluble omps (SOMP-LOS) elicit the highest antibody titers against purified p1.7,16, while the titers of sera elicited by outer membranes and LOS-depleted outer membranes (OM-LOS) are lower but approximately equal. Western immunoblot analysis with the sera against outer membranes from both H44/76 and 2996 cells and purified p1.7,16 indicates that the sera contain only antibodies against outer membrane proteins and not antibodies against LOS.

[0033] Tables 3 and 4 show the endpoint ELISA titers of the sera to H44/76 and 2996 whole cells, respectively. The titers of sera from LOS-depleted outer membranes prepared using Zw3-12, as well as Zw3-14, are shown. The ELISA titers of all three antisera are similar against H44/76 whole cells (Table 3). The serum elicited by the soluble omps and the serum elicited by the LOS-depleted outer membranes appear to approach a plateau stage at exsanguination. The level of antibodies in sera elicited by crude outer membranes appears to increase linearly. In ELISAs against 2996 whole cells (Table 4), the titers of sera elicited by crude outer membranes and those elicited by LOS-depleted outer membranes are approximately equal, and both are lower than the titer of sera elicited by LOS-depleted soluble omps. These results show that the LOS-depleted outer membrane and soluble omp products of this process are extremely low in endotoxin content without significant loss of immunogenicity. In addition, these results show that antibodies against two strains with different serotypes and subtypes (H44/76 and 2996) are elicited by outer membrane products made from a recombinant strain (H13) that expresses the class 1 subtypes of both strains.

#### Bactericidal Activity

[0034] The ability of the LOS-depleted outer membrane and soluble omp preparations to elicit functional antibodies (i.e. antibodies able to induce complement-mediated destruction of meningococcal cells) is tested by determining the bactericidal activity of the sera. The assay for bactericidal activity is described in the Examples. Table 5 shows the results obtained using outer membranes prepared from strain 2996 (subtype p1.5,2) or the recombinant strain H13 (subtypes p1.5,2 and p1.7,16). LOS-depleted outer membranes and soluble outer membrane proteins of 2996 produce antibodies capable of killing a homologous strain of *N. meningitidis*, but not a heterologous strain, H44/76. The LOS-depleted outer membrane preparations made from H13, which expresses the class 1 subtypes of both H44/76 and 2996, elicit bactericidal antibodies against H44/76 whole cells, but not against 2996 whole cells. This lack of bactericidal activity against 2996 is not due to loss during the removal of LOS, however, since the crude outer membranes also do not elicit functional antibodies. As shown above, LOS-depleted outer membrane products made from H13 do elicit antibodies against 2996 cells (Table 4). It is possible that the lack of bactericidal activity against 2996 cells under these conditions is due to weak expression of the p1.5,2 class 1 protein in the H13 strain. This is consistent with observations from Western blots that the H13 strain expresses significantly less p1.5,2 protein than the native p1.7,16 class 1 protein. This problem can be overcome by preparing the LOS-depleted outer membranes from a recombinant strain that expresses the recombinant class 1 protein at a level comparable to that of the native class 1 protein. Clones of H13 with stronger expression of p1.5,2 can also be selected by screening filters containing H13 colonies for reactivity to anti-

p1.5,2 antibodies. Alternatively, bactericidal antibodies may be elicited by increasing the immunization dose of LOS-depleted outer membranes or soluble omps.

#### Utility of the Invention

**[0035]** The method described above is useful for preparing vaccines against *N. meningitidis* and other Gram-negative cocci. Methods of therapy or prophylaxis against diseases (e.g. meningitis) caused by these cocci are thus provided. Previous methods of vaccine preparation follow a strategy of first extracting the outer membrane proteins (omp) from cell walls and then removing as much LOS as possible. The present method differs from previous methods in that it removes the LOS prior to extraction of the outer membrane proteins. As a result, the LOS content is greatly reduced without significant loss of immunogenicity from outer membrane proteins.

**[0036]** The present method can remove LOS to as little as less than 0.01% (wt./wt. total protein) prior to solubilization of omp. The soluble omp preparation contains less than about 3.0 ng LOS per µg protein. This is 40X less endotoxin than reported by Zollinger et al. for their vaccine in 1978 (Zollinger, U.S. Patent No. 4,707,543) and 100X less endotoxin than is currently being tested in Cuba and Brazil (Sierra *et al.*, 1991).

**[0037]** A further advantage is that two types of LOS-depleted preparations are produced, outer membrane complexes and soluble outer membrane proteins, both of which are immunogenic and low in LOS content. A soluble antigen preparation permits greater flexibility in choosing adjuvants and easier administration of the vaccine. It is notable that the preparation of soluble outer membrane proteins is capable of eliciting a functional antibody response in the absence of a vesicular structure. All previous vaccine trials utilize an outer membrane complex or vesicular form (Sierra *et al.*, 1991). In addition, these previous vaccines have low but measurable levels of LOS. In fact, the previous vaccine against serogroup B *N. meningitidis* contains 1% LOS by weight relative to total protein.

**[0038]** The present method is useful for preparing multivalent vaccines. For example, in one embodiment, LOS-depleted outer membranes or soluble omps are made using a mixture of strains of various serogroups, serotypes and subtypes of *N. meningitidis*. In another embodiment, recombinant strains that express a mixture of strain-specific outer membrane epitopes, such as various class 1 protein subtypes, are used as starting material for vaccines with broader protective value. The cloning (Barlow *et al.*, 1987) and sequences of a number of class 1 omps of *N. meningitidis* and the construction of recombinant bacterial strains are previously described (Seid *et al.*, WO 90/06696).

**[0039]** The LOS-depleted outer membrane preparations, including the soluble omps, are also useful as diagnostic reagents, for example, to distinguish antibodies against cell walls or omps from antibodies against coccal capsules or LOS. Furthermore, the immunogenic preparations are useful for raising antibodies that recognize omps or cell walls, but not capsular saccharides.

**[0040]** This method of preparing LOS-depleted outer membranes and soluble omps is expected to be effective on various Gram-negative cocci, since these bacteria have structurally similar outer membranes. For example, LOS-depleted outer membrane products and vaccines can be prepared by this method from other *Neisseria*, such as *Neisseria gonorrhoeae*, and from other Gram-negative cocci, such as *Moraxella* and particularly *M. catarrhalis*.

**[0041]** The following examples specifically illustrate the invention.

#### Examples

##### *N. meningitidis* Strains

**[0042]** *Neisseria meningitidis* H44/76 (B:15:p1.7,16), 2996 (B:2B:p1.5,2), and H13 (B:-:p1.7,16;p1.5,2) cells are kindly supplied by J. T. Poolman, Netherlands. H44/76 was deposited on December 11, 1989 in the Centraal Bureau Voor Schimmelculturen (CBS), Baarn, The Netherlands, under the terms of the Budapest Treaty and is referenced by CBS G35-89. 2996 and H13 are available from the RIVM, The Netherlands. Strain typing is based on the scheme proposed by Frasch (1983).

**[0043]** *N. meningitidis* strains are grown from frozen stock of GC agar media (Difco Laboratories, Detroit, MI) supplemented with dextrose (4 g/L), glutamine (0.1 g/L), cocarboxylase (0.2 mg/L), and ferric nitrate (5 mg/L). Plates are incubated for 6 hours at 35°C in 5% CO<sub>2</sub>. After growing for 6 hours, the colonies from one plate are used to inoculate 100 mL of liquid culture media consisting of 0.2% dialyzed yeast extract, L-glutamic acid (1.3 g/L), L-cysteine-HCl (0.02 g/L), sodium phosphate dihydrate, dibasic (10 g/L), potassium chloride (0.09 g/L), ammonium chloride (1.25 g/L), magnesium sulfate heptahydrate (0.6 g/L), dextrose (5 g/L), and ferric nitrate (100 µM). This liquid culture is grown at 37°C for 18 hours. An aliquot of the 18 hour culture is diluted to 20-30 Klett units or an optical density of 0.1 at 650 nm, and the culture is grown to late exponential phase. Once the cells reach late exponential phase, they are heat killed, sedimented, frozen, and lyophilized.

Preparation of LOS-Depleted Meningococcal Outer Membranes and Soluble Outer Membrane Proteins

**[0044]** TRITON X-100™, BRIJ™, EMPIGEN BB™ and the ZWITTERGENTS™ are available from Calbiochem, San Diego, CA. TWEEN80™ is available from ICN Nutritional Biochemicals, Cleveland, OH.

**[0045]** 1.5 grams of lyophilized, heat killed cells are resuspended in 75 milliliters of a hypotonic solution of 10 mM Hepes-NaOH, pH 7.4, 1 mM EDTA and lysed in an SLM/AMINCO French Pressure Cell. Bacteria are pelleted by centrifugation (5 minutes, 8000 x g, 10°C). The cell lysate is washed with 0.5 M sodium chloride, and the cytoplasmic extract is removed by centrifugation (200,000 x g, one hour, 10°C). Inner membranes are solubilized and removed by centrifugation at 400,000 x g for one hour at 10°C following extraction with 1% TRITON X-100™ in 10 mM Hepes-NaOH, pH 7.4, 1 mM magnesium chloride. This extraction is repeated once. Outer membranes are washed by resuspension in 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, and centrifuged (200,000 x g, one hour, 10°C). They are then extracted twice for one hour each with 1% ZWITTERGENT 3-14™ (w/v) in the same buffer and centrifuged at 400,000 x g for one hour at 10°C. Outer membrane proteins are solubilized by extracting the protein-containing cell walls with 1% ZWITTERGENT 3-14™ (w/v) and 0.5 M sodium chloride for one hour at room temperature and concentrated by 80% ethanol (v/v) precipitation. The concentrated outer membrane proteins are solubilized in 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1% ZWITTERGENT 3-14™, 0.5 M NaCl.

SDS-PAGE and Immunoblotting

**[0046]** Protein profiles and LOS content of outer membrane vesicles (OMV) and solubilized proteins are analyzed in 15% SDS-polyacrylamide gels with the buffer system of Laemmli (1970). The apparatus used is BIO-RAD's (Richmond, CA) Mini Protean II Dual Slab Gel system. Samples are heated for 5 minutes at 100°C in sample buffer containing 0.1 M Tris-HCl, pH 7.0, 25 mM dithiothreitol, 2% sodium dodecyl sulfate (SDS), then adjusted to 6% sucrose. Gels are run at 150 V for 45-60 minutes and either silver stained by the method of Morrissey (1981), or the proteins are transferred onto nitrocellulose for immunoblotting as described (Towbin *et al.*, 1979; Johnson *et al.*, 1984). Blots are blocked for 15 minutes at 37°C in BLOTTO (5% dry milk, 0.05 M Tris-HCl, pH 8.0, 0.15 M, NaCl) and incubated with a 1:500 dilution of sera in BLOTTO for one hour at 37°C. The presence of class 1 outer membrane proteins (OMPs) p1.5,2 and p1.7,16 is ascertained using monoclonal antibodies (supplied by J. T. Poolman). Reactive proteins are visualized with goat anti-mouse IgG and IgM conjugated to horseradish peroxidase (TAGO, Inc., Burlingame, CA), and development follows using 4-chloro-1-naphthol as the substrate.

Protein Quantitation

**[0047]** Total protein content is determined by Pierce's (Rockford, IL) BCA Protein Assay kit using bovine serum albumin as a standard.

Animal Studies

**[0048]** Each group of ten Swiss Webster mice, eight weeks old, are immunized subcutaneously with 25 µg of outer membranes, LOS-depleted outer membranes or LOS-depleted soluble outer membrane proteins in saline with 25 µg of 3-O-deacyl monophosphoryl lipid A (Ribi ImmunoChem Research, Inc., Hamilton, MT) in a volume of 0.2 ml. Three vaccinations are administered at weeks zero, four, and eight. Mice are bled at the same intervals and exsanguinated at week ten. Pooled sera from each group are analyzed by immunoblot and enzyme-linked immunosorbent assay (ELISA). Immunoblotting is performed as described above and the sera tested at a 1:500 dilution against outer membrane complexes from H44/76 and 2996 cells and purified p1.7,16 outer membrane protein. ELISA assays utilize either whole cells of strains H44/76 or 2996 or purified class 1 omp. Bacteria are inactivated at 56°C for one hour and diluted in sterile phosphate buffered saline (PBS: 27 mM KCl, 43 mM Na<sub>2</sub>HPO<sub>4</sub> • 7 H<sub>2</sub>O, 15 mM KH<sub>2</sub>PO<sub>4</sub>, 5 mM MgCl<sub>2</sub> • 6 H<sub>2</sub>O, 1.4 M NaCl) to an OD<sub>620</sub> of 0.01-0.1. 96-well flat-bottomed microtiter plates (Nunc) are coated with 100 µl of cells and dried at 37°C overnight in a dry incubator. Plates are washed three times with 0.05% TWEEN20™ in PBS (Wash Buffer), followed by incubation for one hour with 100 µl of 0.1% gelatin in PBS for blocking. Plates are washed three times with Wash Buffer. 0.1% gelatin and 0.05% TWEEN20™ in PBS are used to dilute the control and test sera, and 100 µl of these dilutions are added to the plates and incubated at room temperature for 90 minutes. Plates are again washed three times, 100 µl of 1:1000 dilution of goat anti-mouse IgG and IgM conjugated to alkaline phosphatase (TAGO) are added, and the mixture is incubated at room temperature for one hour. Plates are washed three times, followed by a one hour incubation with 100 µl of the substrate nitrophenyl phosphate (Sigma) at 1.0 mg/ml in 1 M diethanolamine/0.5 mM magnesium chloride. The reaction is stopped by addition of 100 µl of 2 N NaOH, and the absorbance at 410 nm is read.

**[0049]** ELISA's to detect antibodies to the class 1 outer membrane protein p1.7,16 are also performed. 96-well flat-

bottomed microtiter plates are coated with 100  $\mu$ l of purified p1.7,16 at 5  $\mu$ g/ml in 14 mM sodium carbonate/36 mM sodium bicarbonate, pH 9.6, 0.02% sodium azide buffer at 37°C for 90 minutes. Plates are washed six times with PBS/0.1% TWEEN20™ (Wash Buffer). Serial dilutions of murine sera are made in PBS/0.05% TWEEN20™, 100  $\mu$ l is added to each washed plate, and each plate is incubated for one hour at 37°C. Plates are again washed six times with Wash Buffer. 100  $\mu$ l of a 1:2000 dilution of goat anti-mouse IgG and IgM conjugated to alkaline phosphatase are added, and the mixture is incubated for one hour at 37°C. Plates are washed as before, 100  $\mu$ l of 1 mg/ml solution of nitrophenyl phosphate in diethanolamine are added, and the plates are allowed to incubate for one hour at room temperature. The reaction is stopped with 50  $\mu$ l of 3 N sodium hydroxide, and the absorbance at 405 nm is read.

#### Bactericidal Assay

**[0050]** The assay procedure is modified from Høiby *et al.* (1991). *N. meningitidis* strains are grown from frozen stock of GC agar media (difco Laboratories, Detroit, MI) supplemented with dextrose (4 g/L), glutamine (0.1 g/L), cocarboxylase (0.2 mg/L), and ferric nitrate (5 mg/L). Plates are incubated for 6 hours at 35°C in 5% CO<sub>2</sub>. After growing for 6 hours, the colonies from one plate are used to inoculate 100 mL of liquid culture media consisting of 0.2% dialyzed yeast extract, L-glutamic acid (1.3 g/L), L-cysteine-HCl (0.02 g/L), sodium phosphate dihydrate, dibasic (10 g/L), potassium chloride (9.09 g/L), and ammonium chloride (1.25 g/L). This liquid culture is grown at 37°C for 18 hours. An aliquot of the 18 hour culture is diluted to 20-30 Klett units or an optical density of 0.1 at 650 nm, and the culture is grown to late exponential phase. Once the cells reach late exponential phase, they are used in the bactericidal assay.

**[0051]** The bactericidal assay is carried out by mixing 10  $\mu$ L *N. meningitidis* cells (about 2-4,000 bacteria), 10  $\mu$ L complement (20% normal human sera), 25  $\mu$ L PBS with 0.015 mM CaCl<sub>2</sub> and 0.5 mM MgCl<sub>2</sub> (PCM), and 5  $\mu$ L diluted serum (PCM as diluent). The source of complement is pre-tested for lack of bactericidal activity by itself. The mix is incubated at 36°C for 45 minutes, diluted at that time with 200  $\mu$ L PCM, and 50  $\mu$ L are plated onto GC agar plates. The culture plates are incubated for 24 hours at 35-36°C with 5% CO<sub>2</sub>. Colonies are then counted and bactericidal activity expressed as % control (no serum added). Titers are reported as the reciprocal of the dilution at which 50% of the bacteria in the assay are killed, as extrapolated from a plot of % killing vs. dilution. All sera are routinely tested at week 10. The highest concentration of sera tested is 1/50; any sera that do not kill at 1/50 are reported to have a titer of <50. Positive control antiserum, prepared against whole 2996 cells, is capable of utilizing the complement source to kill strain 2996 under these conditions.

TABLE 1

Endotoxin and Protein Content of Outer Membrane Preparations		
Preparation	Endotoxin (Eu)	Protein (Mg)
Outer Membranes	22,360	448
LOS-depleted Outer Membranes	8	175
LOS-depleted Soluble Outer Membrane Proteins	7	30
Starting material for these preparations is 1.5 g dry weight of H13 cells. Endotoxin units (Eu) are measured by turbidometric assay using <i>E. coli</i> lipopolysaccharide (LPS) as a standard, where 1 Eu = 0.1 ng <i>E. coli</i> LPS.		

TABLE 2

Endpoint Titers to Purified p1.7,16				
Immunogen	Endpoint titers at weeks after primary immunization			
	0	4	8	10
Outer Membranes	<100	6,287	63,946	142,416
OM-LOS	<100	2,234	70,835	129,159
SOMP-LOS	<100	20,355	192,939	199,068



## EP 0 624 376 B1

OM-LOS, LOS-depleted outer membranes.  
SOMP-LOS, LOS-depleted soluble outer membrane proteins.

TABLE 3

Endpoint ELISA Titers to H44/76 Whole Cells				
Immunogen	Endpoint titers at weeks after primary immunization			
	0	4	8	10
Outer Membranes	248	21,726	122,674	388,553
Zw3-12 OM-LOS	0	30,345	297,971	90,546
Zw3-14 OM-LOS	6070	10,877	298,854	346,163
SOMP-LOS	0	30,728	270,977	320,328

Zw3-12 OM-LOS, LOS-depleted outer membranes prepared with Zw3-12.

Zw3-14 OM-LOS, LOS-depleted outer membranes prepared with Zw3-14.

SOMP-LOS, LOS-depleted soluble outer membrane proteins.

TABLE 4

Endpoint ELISA Titers to 2996 Whole Cells				
Immunogen	Endpoint titers at weeks after primary immunization			
	0	4	8	10
Outer Membranes	0	7,120	71,166	137,506
Zw3-12 OM-LOS	0	9,437	130,823	79,852
Zw3-14 OM-LOS	0	6,970	231,942	118,969
SOMP-LOS	0	14,149	128,629	202,402

Zw3-12 OM-LOS, LOS-depleted outer membranes prepared with Zw3-12.

Zw3-14 OM-LOS, LOS-depleted outer membranes prepared with Zw3-14.

SOMP-LOS, LOS-depleted soluble outer membrane proteins.

TABLE 5

Bactericidal Activity of Antisera to LOS-Depleted Outer Membrane Preparations		
Immunogen	Bactericidal Titer of Strain	
	H44/76	2996
Negative control (wk 0)	<50	<50
H13 Outer Membranes	1,100	<50
H13 OM+partial LOS	800	<50
H13 OM-LOS	900	<50
H13 SOMP-LOS	1,000	<50
2996 Outer Membranes	<50	600
2996 OM-LOS	<50	225
2996 SOMP-LOS	<50	150

OM+partial LOS, outer membranes extracted once with Zw3-14 or twice with Zw3-12.

OM-LOS, LOS-depleted outer membranes.

SOMP-LOS, LOS-depleted soluble outer membrane proteins.

Titers are the reciprocal of the dilution that gave 50% killing. The highest concentration of sera tested is 1/50; any sera that do not kill at 1/50 are reported to have a titer of <50.

### Bibliography

[0055] Barlow, A.K., *et al.* (1987), "Molecular cloning and expression of *Neisseria meningitidis* Class 1 outer membrane protein in *Escherichia coli* K-12". *Infection and Immunity* 55(11):2734-2740.

[0056] Frasch, C.E. (1983), "Immunization against *Neisseria meningitidis*". In *Medical Microbiology* (eds. C.S.F. Easman and J. Jeljaszewicz), Academic Press, New York, Vol. 2, pp. 115-144.

[0057] Goldschneider, I., *et al.* (1969), "Human immunity to the meningococcus. II. Development of natural immunity". *J. Exp. Med.* 129:1327-1348.

[0058] Hankins, W.A., *et al.* (1982), "Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y and W135". *Proc. Soc. Exp. Biol. Med.* 169:54-57.

[0059] Høiby, E.A., *et al.* (1991), *NIPH Annals* 14(2):147-155. Johnson, D.A., *et al.* (1984), *Gene Anal. Technol.* 1:3-8. Laemmli, U.K. (1970), *Nature* 227:680-685.

[0060] Morrissey, J.H. (1981), *Anal. Biochem.* 117:307-310. Seid, R.C., *et al.*, WO 90/06696, "Meningococcal Class 1 Outer-Membrane Protein Vaccine", June 28, 1990.

[0061] Sierra, G. V. G., *et al.* (1991), "Vaccine against group B *Neisseria meningitidis*: protection trial and mass vaccination results in Cuba". *NIPH Annals* 14(2):195-210. Towbin, H., *et al.* (1979), *Proc. Natl. Acad. Sci. USA* 76:4350-4355.

[0062] Tsai, C.M., *et al.* (1981), "Five structural classes of major outer membrane proteins in *Neisseria meningitidis*". *J. Bacteriol.* 146:69-78.

[0063] Zollinger, W.D. (1990), "New and improved vaccines against meningococcal disease". In *New Generation Vaccines* (eds. G.C. Woodrow and M.M. Levine), Marcel Dekker, Inc., New York, pp. 325-348.

[0064] Zollinger, W.D., *et al.*, US Patent No. 4,707,543, "Process for the Preparation of Detoxified Polysaccharide-Outer Membrane Protein Complexes, and Their Use As Antibacterial Vaccines", November 17, 1987.

### Equivalents

[0065] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are

intended to be encompassed in the scope of the following claims.

## Claims

1. A method of preparing lipooligosaccharide-depleted outer membranes from total membranes of a Gram-negative coccus, said method comprising:

a) extracting total membranes of the coccus with a polyoxyethylene detergent to produce outer membranes depleted of inner membranes;

and

b) extracting the outer membranes produced by step a) with a zwitterionic betaine detergent to produce lipooligosaccharide-depleted outer membranes.

2. The method of Claim 1, wherein the coccus is selected from the group consisting of *Neisseria* and *Moraxella*.

3. The method of Claim 2, wherein the coccus is selected from the group consisting of *Neisseria meningitidis*, *Neisseria gonorrhoeae* and *Moraxella catarrhalis*.


4. The method of Claim 1, wherein the polyoxyethylene detergent in step a) is selected from the group consisting of:

a) TRITON X-100™;

b) BRIJ35™; and

c) TWEEN80™.

5. The method of Claim 1, wherein the zwitterionic betaine detergent has the formula:



where R<sub>1</sub> is an alkyl chain with greater than 10 carbons and less than or equal to 16 carbons, R<sub>2</sub> is a carboxyl group or a sulfonyl group, and n is greater than 1.

6. The method of Claim 5, wherein the zwitterionic betaine detergent is selected from the group consisting of:

a) ZWITTERGENT 3-12™;

b) ZWITTERGENT 3-14™; and

c) EMPIGEN BB™.

7. The method of Claim 1, wherein step a) is performed more than once before proceeding with step b).

8. The method of Claim 1, wherein step b) is performed more than once.

9. The method of Claim 1, further comprising extracting the outer membranes produced by step b) with a zwitterionic betaine detergent in salt buffer to produce a fraction containing soluble outer membrane proteins and a fraction containing insoluble outer membrane proteins and cell wall components.

10. The method of Claim 9, wherein the zwitterionic betaine detergent is ZWITTERGENT 3-14™, and the salt buffer is about 0.1 to about 0.5 M NaCl and further comprising concentrating the soluble outer membrane proteins.

11. Isolated lipooligosaccharide-depleted outer membranes produced by the method of Claim 1, of Claim 4, of Claim 6, of Claim 9 and Claim 10.

12. The fraction produced by the method of Claim 9.

13. The fraction produced by the method of Claim 10.

5 14. A method of preparing a composition capable of eliciting a bactericidal antibody against a Gram-negative coccus, said method comprising:

- 10 a) obtaining total membranes of a Gram-negative coccus;  
b) extracting the total membranes with a polyoxyethylene detergent to produce outer membranes depleted of inner membranes;  
c) extracting the outer membranes produced by step b) with a zwitterionic betaine detergent to produce lipooligosaccharide-depleted outer membranes; and combining with a physiologically acceptable vehicle, thereby preparing a composition capable of eliciting a bactericidal antibody against the Gram-negative coccus.

15 15. The method of Claim 14, wherein the coccus is selected from the group consisting of *Neisseria* and *Moraxella*.

16. The method of Claim 15, wherein the coccus is selected from the group consisting of *Neisseria meningitidis*, *Neisseria gonorrhoeae* and *Moraxella Catarrhalis*.


20 17. The method of Claim 16, wherein the *Neisseria meningitis* belongs to serogroup B.

18. The method of Claim 14, wherein more than one strain of Gram-negative coccus is used in step a), said strains belonging to more than one serogroup, serotype, or subtype of the bacterium.

25 19. The method of Claim 14, wherein the Gram-negative coccus is recombinant and the recombinant coccus expresses more than one subtype of class 1 outer membrane protein.

20. The method of Claim 14, wherein the polyoxyethylene detergent in step b) is selected from the group consisting of:

- 30 a) TRITON X-100;  
b) BRIJ35™; and  
c) TWEEN80™;  
wherein the zwitterionic betaine detergent in step c) has the formula:



45 where R<sub>1</sub> is an alkyl chain with greater than 10 carbons and less than or equal to 16 carbons, and R<sub>2</sub> is a carboxyl group or a sulfonyl group, and n is greater than 1.

21. The method of Claim 20, wherein the zwitterionic betaine detergent is selected from the group consisting of:

- 50 a) ZWITTERGENT 3 - 12™;  
b) ZWITTERGENT 3-14™; and  
c) EMPIGEN BB™.

22. The method of Claim 14, further comprising:

- 55 d) extracting the outer membrane proteins produced by step c) with a zwitterionic betaine detergent in a salt buffer to obtain soluble outer membrane proteins;  
wherein the zwitterionic betaine detergent is ZWITTERGENT 3-14™ and the salt buffer is about 0.1 to about

0.5 M NaCl.

23. A vaccine, comprising a composition prepared by the method of Claim 14, Claim 16, Claim 17, Claim 18, Claim 19, Claim 20, Claim 21 and Claim 22.

24. A composition according to Claim 11, Claim 12, Claim 13 or Claim 23 for use in therapy.

25. Use of a composition according to Claim 11, Claim 12, Claim 13 or Claim 23 for the manufacture of a medicament for prophylaxis or therapy against disease caused by a Gram-negative coccus.

26. Use according to Claim 25, wherein the disease is meningitis.

27. Use of a composition according to Claim 11, Claim 12, Claim 13 or Claim 23 for the manufacture of a medicament for eliciting antibodies to said composition.

28. Use according to Claim 27, wherein said antibodies recognize the outer membranes of a Gram-negative coccus and do not cross-react with the lipooligosaccharides of said Gram-negative coccus.

29. Use according to Claim 27, wherein the coccus is selected from the group consisting of *Neisseria* and *Moraxella*.

30. Use according to Claim 29, wherein the coccus is selected from the group consisting of *Neisseria meningitidis*, *Neisseria gonorrhoeae* and *Moraxella catarrhalis*.

#### Patentansprüche

1. Verfahren zur Herstellung Lipooligosaccharid-verminderter Außenmembranen aus Gesamtmembranen einer gramnegativen Kokke, wobei das Verfahren umfaßt:

a) Extraktion von Gesamtmembranen der Kokke mit einem Polyoxyethylen-Detergenz zur Herstellung Innenmembran-verminderter Außenmembranen;

und

b) Extraktion der durch Schritt a) hergestellten Außenmembranen mit einem zwitterionischen Betain-Detergenz zur Herstellung Lipooligosaccharid-verminderter Außenmembranen.

2. Verfahren nach Anspruch 1, wobei die Kokke aus der Gruppe, bestehend aus *Neisseria* und *Moraxella*, ausgewählt ist.

3. Verfahren nach Anspruch 2, wobei die Kokke aus der Gruppe, bestehend aus *Neisseria meningitidis*, *Neisseria gonorrhoeae* und *Moraxella catarrhalis*, ausgewählt ist.


4. Verfahren nach Anspruch 1, wobei das Polyoxyethylen-Detergenz in Schritt a) aus der Gruppe, bestehend aus:

a) TRITON X-100™;

b) BRIJ35™; und


c) TWEEN80™ ausgewählt ist.

5. Verfahren nach Anspruch 1, wobei das zwitterionische Betain-Detergenz die Formel hat:



wobei R<sub>1</sub> eine Alkylkette mit mehr als 10 Kohlenstoffatomen und weniger oder gleich 16 Kohlenstoffatomen ist, R<sub>2</sub> eine Carboxylgruppe oder eine Sulfonylgruppe ist, und n größer als 1 ist.

6. Verfahren nach Anspruch 5, wobei das zwitterionische Betain-Detergenz aus der Gruppe, bestehend aus:
  - a) ZWITTERGENT 3-12™;
  - b) ZWITTERGENT 3-14™; und
  - c) EMPIGEN BB™ ausgewählt ist.
7. Verfahren nach Anspruch 1, wobei Schritt a) vor der Behandlung mit Schritt b) mehr als einmal durchgeführt wird.
8. Verfahren nach Anspruch 1, wobei Schritt b) mehr als einmal durchgeführt wird.
9. Verfahren nach Anspruch 1, weiterhin umfassend die Extraktion der durch Schritt b) hergestellten Außenmembranen mit einem zwitterionischen Betain-Detergenz in Salzpuffer zur Herstellung einer löslichen Außenmembran-Proteine enthaltenden Fraktion und einer unlöslichen Außenmembran-Proteine und Zellwand-Bestandteile enthaltenden Fraktion.
10. Verfahren nach Anspruch 9, wobei das zwitterionische Betain-Detergenz ZWITTERGENT 3-14™ ist, und der Salzpuffer etwa 0,1 bis etwa 0,5 M NaCl ist und weiterhin umfassend die Konzentrierung der löslichen Außenmembran-Proteine.
11. Isolierte Lipooligosaccharid-verminderte Außenmembranen, hergestellt durch das Verfahren nach Anspruch 1, Anspruch 4, Anspruch 6, Anspruch 9 und Anspruch 10.
12. Fraktion, hergestellt durch das Verfahren nach Anspruch 9.
13. Fraktion, hergestellt durch das Verfahren nach Anspruch 10.
14. Verfahren zur Herstellung einer Zusammensetzung, die einen bakteriziden Antikörper gegen eine gramnegative Kokke hervorrufen kann, wobei das Verfahren umfaßt:
  - a) Gewinnung von Gesamtmembranen einer gramnegativen Kokke;
  - b) Extraktion der Gesamtmembranen mit einem Polyoxyethylen-Detergenz zur Herstellung von Innenmembran-verminderten Außenmembranen;
  - c) Extraktion der nach Schritt b) hergestellten Außenmembranen mit einem zwitterionischen Betain-Detergenz zur Herstellung von Lipooligosaccharid-verminderten Außenmembranen; und Vereinigen mit einem physiologisch verträglichen Träger, wodurch eine Zusammensetzung, die einen bakteriziden Antikörper gegen die gramnegative Kokke hervorruft, zubereitet wird.
15. Verfahren nach Anspruch 14, wobei die Kokke aus der Gruppe, bestehend aus Neisseria und Moraxella, ausgewählt ist.
16. Verfahren nach Anspruch 15, wobei die Kokke aus der Gruppe, bestehend aus Neisseria meningitidis, Neisseria gonorrhoeae und Moraxella catarrhalis, ausgewählt ist.
17. Verfahren nach Anspruch 16, wobei Neisseria meningitis zu der serologischen Gruppe B gehört.
18. Verfahren nach Anspruch 14, wobei in Schritt a) mehr als ein gramnegativer Kokken-Stamm, der zu mehr als einer serologischen Gruppe, serologischem Typ oder Subtyp des Bakteriums gehört, verwendet wird.
19. Verfahren nach Anspruch 14, wobei die gramnegative Kokke rekombinant ist und die rekombinante Kokke mehr als ein Außenmembran-Protein vom Subtyp der Klasse 1 exprimiert.
20. Verfahren nach Anspruch 14, wobei das Polyoxyethylen-Detergenz in Schritt b) aus einer Gruppe, bestehend aus:
  - a) TRITON X-100™;
  - b) BRIJ35™; und
  - c) TWEEN80™; ausgewählt ist,wobei das zwitterionische Betain-Detergenz in Schritt c) die Formel hat:



wobei R<sub>1</sub> eine Alkylkette mit mehr als 10 Kohlenstoffatomen und weniger oder gleich 16 Kohlenstoffatomen ist, R<sub>2</sub> eine Carboxylgruppe oder eine Sulfonylgruppe ist, und n größer als 1 ist.

21. Verfahren nach Anspruch 20, wobei das zwitterionische Betain-Detergenz aus einer Gruppe, bestehend aus:

- a) ZWITTERGENT 3-12™;
- b) ZWITTERGENT 3-14™; und
- c) EMPIGEN BB™, ausgewählt ist.

22. Verfahren nach Anspruch 14, weiterhin umfassend:

- d) Extraktion der durch Schritt c) hergestellten Außenmembran-Proteine mit einem zwitterionischen Betain-Detergenz in einem Salzpuffer zur Gewinnung löslicher Außenmembran-Proteine; wobei das zwitterionische Betain-Detergenz ZWITTERGENT 3-14™ ist und der Salzpuffer etwa 0,1 bis etwa 0,5 M NaCl ist.

23. Impfstoff, umfassend eine durch das Verfahren nach Anspruch 14, Anspruch 16, Anspruch 17, Anspruch 18, Anspruch 19, Anspruch 20, Anspruch 21 und Anspruch 22 hergestellte Zusammensetzung.

24. Zusammensetzung nach Anspruch 11, Anspruch 12, Anspruch 13 oder Anspruch 23 zur Verwendung in der Therapie.

25. Verwendung einer Zusammensetzung nach Anspruch 11, Anspruch 12, Anspruch 13 oder Anspruch 23 zur Herstellung eines Arzneimittels für die Prophylaxe oder Therapie gegen eine durch eine gramnegative Kokke verursachte Erkrankung.

26. Verwendung nach Anspruch 25, wobei die Erkrankung Meningitis ist.

27. Verwendung einer Zusammensetzung nach Anspruch 11, Anspruch 12, Anspruch 13 oder Anspruch 23 zur Herstellung eines Arzneimittels zur Erzeugung von Antikörpern gegen die Zusammensetzung.

28. Verwendung nach Anspruch 27, wobei die Antikörper die Außenmembranen einer gramnegativen Kokke erkennen und mit den Lipooligosacchariden der gramnegativen Kokke nicht kreuzreagieren.

29. Verwendung nach Anspruch 27, wobei die Kokke aus der Gruppe, bestehend aus Neisseria und Moraxella, ausgewählt ist.

30. Verwendung nach Anspruch 29, wobei die Kokke aus der Gruppe, bestehend aus Neisseria meningitidis, Neisseria gonorrhoeae und Moraxella catarrhalis, ausgewählt ist.

## Revendications

1. Méthode de préparation de membranes externes dépourvues de lipooligosaccharides à partir de membranes totales de coque gram-négatif, ladite méthode comprenant :

- a) l'extraction de membranes totales du coque par un détergent de type polyoxyéthylène pour produire des membranes externes dépourvues de membranes internes ;
- et
- b) l'extraction des membranes externes produites par l'étape a) avec un détergent de type bétaine zwitterioni-

que pour produire des membranes externes dépourvues de lipooligosaccharides.


2. Méthode de la revendication 1, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria* et *Moraxella*.

3. Méthode de la revendication 2, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria meningitidis*, *Neisseria gonorrhoeae* et *Moraxella catarrhalis*.

4. Méthode de la revendication 1, dans laquelle le détergent de type polyoxyalkylène de l'étape a) est choisi dans l'ensemble consistant en :

- a) TRITON X-100™
- b) BRIJ35™ ; et
- c) TWEEN 80™.

5. Méthode de la revendication 1, dans laquelle le détergent de type bétaine zwitterionique a la formule :



dans laquelle R<sub>1</sub> représente une chaîne alkylque avec plus de 10 atomes de carbone et jusqu'à 16 atomes de carbone ou moins, R<sub>2</sub> représente un groupe carboxyle ou un groupe sulfonyle et n est supérieur à 1.

6. Méthode de la revendication 5 dans laquelle le détergent de type bétaine zwitterionique est choisi dans l'ensemble consistant en :

- a) ZWITTERGENT 3-12™;
- b) ZWITTERGENT 3-14™ ; et
- c) EMPIGEN BB™.

7. Méthode de la revendication 1, dans laquelle l'étape a) est mise en oeuvre plus d'une fois avant de mettre en oeuvre l'étape b).

8. Méthode de la revendication 1, dans laquelle l'étape b) est mise en oeuvre plus d'une fois.

9. Méthode de la revendication 1, comprenant en outre l'extraction des membranes externes produites par l'étape b) avec un détergent de type bétaine zwitterionique dans un tampon salin pour produire une fraction contenant des protéines de membranes externes solubles et une fraction contenant des protéines de membranes externes insolubles et des composants de parois cellulaires.

10. Méthode de la revendication 9, dans laquelle le détergent de type bétaine zwitterionique est du ZWITTERGENT 3-14™, et le tampon salin est du NaCl d'environ 0,1 à environ 0,5 M, et comprend en outre la concentration des protéines de membranes externes solubles.

11. Membranes externes isolées dépourvues de lipooligosaccharides produites par la méthode de la revendication 1, de la revendication 4, de la revendication 6, de la revendication 9 et de la revendication 10.

12. Fraction produite par la méthode de la revendication 9.

13. Fraction produite par la méthode de la revendication 10.

14. Méthode de préparation d'une composition capable de produire un anticorps bactéricide contre un coque gram-négatif, ladite méthode comprenant :



a) l'obtention de membranes totales d'un coque gram-négatif ;  
 b) l'extraction des membranes totales avec un détergent de type polyoxyéthylène pour produire des membranes externes dépourvues de membranes internes ;  
 c) l'extraction des membranes externes produites par l'étape b) avec un détergent de type bétaine zwitterionique pour produire des membranes externes dépourvues de lipooligosaccharides ; et la combinaison avec un véhicule physiologiquement acceptable, en préparant ainsi une composition capable de produire un anticorps bactéricide contre le coque gram-négatif.

15. Méthode de la revendication 14, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria* et *Moraxella*.

16. Méthode de la revendication 15, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria meningitidis*, *Neisseria gonorrhoeae* et *Moraxella catarrhalis*.

17. Méthode de la revendication 16, dans laquelle le *Neisseria meningitis* appartient au sérotype B.


18. Méthode de la revendication 14, dans laquelle on utilise dans l'étape a) plusieurs souches de coque gram-négatif, lesdites souches appartenant à plus d'un sérotype, sérotype, ou sous-type de la bactérie.

19. Méthode de la revendication 14, dans laquelle le coque gram-négatif est recombinant, et le coque recombinant exprime plus d'un sous-type de protéines de membrane externe de classe 1.

20. Méthode de la revendication 14, dans laquelle le détergent de type polyoxyalkylène de l'étape b) est choisi dans l'ensemble consistant en :

a) TRITON X-100™  
 b) BRIJ35™ ; et  
 c) TWEEN 80™.

dans laquelle le détergent de type bétaine zwitterionique de l'étape c) a la formule :



dans laquelle  $\text{R}_1$  représente une chaîne alkylique avec plus de 10 atomes de carbone et jusqu'à 16 atomes de carbone ou moins,  $\text{R}_2$  représente un groupe carboxyle ou un groupe sulfonyl et  $n$  est supérieur à 1.

21. Méthode de la revendication 20, dans laquelle le détergent de type bétaine zwitterionique est choisi dans l'ensemble consistant en :

a) ZWITTERGENT 3-12™;  
 b) ZWITTERGENT 3-14™ ; et  
 c) EMPIGEN BB™.

22. Méthode de la revendication 14, comprenant en outre :

d) l'extraction des protéines de membranes externes produites par l'étape c) avec un détergent de type bétaine zwitterionique dans un tampon salin pour obtenir des protéines de membranes externes solubles ;  
 dans laquelle le détergent de type bétaine zwitterionique est du ZWITTERGENT 3-14™, et le tampon salin est du NaCl d'environ 0,1 à environ 0,5 M.

23. Vaccin, comprenant une composition préparée par la méthode de la revendication 14, de la revendication 16, de la revendication 17, de la revendication 18, de la revendication 19, de la revendication 20, de la revendication 21 et

de la revendication 22.

- 5
- 24.** Composition selon la revendication 11, la revendication 12, la revendication 13 ou la revendication 23 pour une utilisation en thérapie.
- 25.** Utilisation d'une composition selon la revendication 11, la revendication 12, la revendication 13 ou la revendication 23, pour la fabrication d'un médicament pour la prophylaxie ou le traitement d'une maladie provoquée par un coque gram-négatif.
- 10 **26.** Utilisation selon la revendication 25, dans laquelle la maladie est une méningite.
- 27.** Utilisation d'une composition selon la revendication 11, la revendication 12, la revendication 13 ou la revendication 23 pour la fabrication d'un médicament destiné à la production d'anticorps contre ladite composition.
- 15 **28.** Utilisation selon la revendication 27, dans laquelle lesdits anticorps reconnaissent les membranes externes d'un coque gram-négatif et ne réagissent pas en réaction croisée avec les lipooligosaccharides dudit coque gram-négatif.
- 20 **29.** Utilisation selon la revendication 27, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria* et *Moraxella*.
- 30.** Utilisation selon la revendication 29, dans laquelle le coque est choisi dans l'ensemble consistant en *Neisseria meningitidis*, *Neisseria gonorrhoeae* et *Moraxella catarrhalis*.

25

30

35

40

45

50

55

**Preparation of LOS-Depleted *Neisseria meningitidis* Outer  
Membrane Proteins**

